RAS proto-oncogene in medullary thyroid carcinoma (Q26796901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Branca M. Cavaco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Valeriano Leite

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Margarida M Moura

1

0 references

Branca M Cavaco

2

0 references

Valeriano Leite

3

0 references

language of work or name

English

0 references

publication date

October 2015

0 references

published in

Endocrine-Related Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

R235-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26285815%20AND%20SRC:MED&resulttype=core&format=json

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

High-resolution analysis of alterations in medullary thyroid carcinoma genomes

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Cabozantinib: a review of its use in patients with medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Isolation of a transforming sequence from a human bladder carcinoma cell line

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Activation of a novel human transforming gene, ret, by DNA rearrangement

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Update on medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

The PDCD4/miR-21 pathway in medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Advances and controversies in the diagnosis and management of medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Risk estimation and screening in families of patients with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

AN UNIDENTIFIED VIRUS WHICH CAUSES THE RAPID PRODUCTION OF TUMOURS IN MICE.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Mechanism of activation of a human oncogene

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Proteins regulating Ras and its relatives

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Frequency of TERT promoter mutations in human cancers

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Array comparative genomic hybridization and its applications in cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

RAS oncogenes: weaving a tumorigenic web

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

C-Cell Hyperplasia Preceding Medullary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Lessons Learned from the Management of a Rare Genetic Cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

In vitro isolation of stable rat sarcoma viruses

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Medullary thyroid cancer: management guidelines of the American Thyroid Association

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

An update on clinical trials of targeted therapies in thyroid cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Point mutations of ras and Gs alpha subunit genes in thyroid tumors.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Nucleotide Sequence of the p21 Transforming Protein of Harvey Murine Sarcoma Virus

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Nucleotide Sequence of the Oncogene Encoding the p21 Transforming Protein of Kirsten Murine Sarcoma Virus

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Histogenesis of medullary carcinoma of the thyroid

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Akt phosphorylates and regulates Pdcd4 tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

A comprehensive survey of Ras mutations in cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Activation of K-RAS by co-mutation of codons 19 and 20 is transforming

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

RET proto-oncogene in the development of human cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Medullary thyroid cancer: options for systemic therapy of metastatic disease?

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Specific pattern of RAS oncogene mutations in follicular thyroid tumors

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

BRAF T1796A transversion mutation in various thyroid neoplasms.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Point mutations of ras oncogenes are an early event in thyroid tumorigenesis

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Farnesyl transferase inhibitors in clinical development

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

mTOR activation in medullary thyroid carcinoma with RAS mutation.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

BRAF mutation in thyroid cancer

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021

Medullary thyroid carcinoma: The third most common thyroid cancer reviewed

1 reference

https://api.crossref.org/works/10.1530%2FERC-15-0070

7 January 2021